Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GH Research ( (GHRS) ) has provided an update.
GH Research PLC announced its acceptance to present at the 64th American College of Neuropsychopharmacology annual meeting in January 2026, highlighting results from its GH001-TRD-201 clinical trial. The trial demonstrated significant improvements in patients with treatment-resistant depression, showing reductions in illness severity, anxiety symptoms, and enhancements in quality of life. These findings suggest that GH001 could provide durable therapeutic benefits with infrequent retreatments, potentially enhancing the company’s position in the psychiatric treatment market.
The most recent analyst rating on (GHRS) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC operates in the biopharmaceutical industry, focusing on the development of novel treatments for psychiatric and neurological disorders. The company is particularly known for its work on treatment-resistant depression, utilizing innovative compounds such as GH001, a synthetic form of mebufotenin.
Average Trading Volume: 320,028
Technical Sentiment Signal: Buy
Current Market Cap: $869.3M
Find detailed analytics on GHRS stock on TipRanks’ Stock Analysis page.